Sobi (Swedish Orphan Biovitrum) Deep Dive Research Report
Investor-Grade Analysis | March 2026
FORWARD-LOOKING DISCLAIMER: This report contains forward-looking statements based on current expectations and assumptions. Actual results may differ materially due to risks including regulatory decisions, competitive dynamics, clinical trial outcomes, and macroeconomic factors. Financial projections are estimates only. This is not investment advice.
Executive Summary
FY 2024 Revenue
SEK 26.0B
+19% CER
Adjusted EBITA
SEK 9.4B
36% margin
Net Income
SEK 3.9B
+18% YoY
Market Cap
SEK 130B
~$12.5B USD
Employees
1,806
+3.8% YoY
2030 Target
SEK 55B
~2x growth
Company Overview
Swedish Orphan Biovitrum AB (publ), trading as Sobi (OMX Stockholm: SOBI), is a global biopharmaceutical company specializing in rare diseases affecting small patient populations across haematology, immunology, and specialty care therapeutic areas.
Key Metric
Value
Headquarters
Stockholm, Sweden
Founded
2010 (merger of Biovitrum and Swedish Orphan International)
Stock Exchange
Nasdaq Stockholm (SOBI)
Global Presence
Operations in 70+ countries; regional hubs in Basel and Waltham, MA
Revenue Mix by Segment (FY 2024)
Revenue Growth Trajectory (SEK Billions)
1. Company History
Formation and Key Milestones
Swedish Orphan International was founded in 1988 as a pioneer in orphan drug distribution across Europe. Biovitrum was established in 2001 through a spin-off from Pharmacia (later Pfizer).
In May 2010, Biovitrum acquired Swedish Orphan International for $493 million, creating Swedish Orphan Biovitrum AB (Sobi).
Year
Event
Significance
2010
Formation of Sobi
Merger creates rare disease leader
2016
EU launch of Elocta and Alprolix
Entry into hemophilia market
2018
Acquisition of Gamifant
Transformational HLH treatment
2019
Acquisition of Doptelet
Expanded haematology portfolio
2021
Aspaveli/Empaveli license
Added PNH franchise
2023
CTI BioPharma acquisition ($1.7B)
Added Vonjo for myelofibrosis
2026
Arthrosi acquisition ($1.5B)
Added pozdeutinurad for gout
3. Leadership / C-Suite
Guido Oelkers - President & CEO
Detail
Information
Age
60 (born 1965)
Nationality
German
Education
PhD Strategic Management, University of South Australia; M.Sc. Economics, South Bank University London
Tenure
Since May 2017
Previous Roles
CEO BSN Medical; President & CEO Gambro; CEO Invida; Executive roles at Aventis, Nycomed, DKSH Group
Executive Committee
Name
Title
Guido Oelkers
Chief Executive Officer
Henrik Stenqvist
Chief Financial Officer
Lydia Abad-Franch
CMO, Head of R&D and Medical Affairs
Duane H. Barnes
Head of North America
Sofiane Fahmy
Head of Europe
Norbert Oppitz
Head of International
Daniel Rankin
Head of Strategy & Corporate Development
Christine Wesström
Head of Technical Operations
4. Drug Portfolio
Haematology Portfolio
Product
FY 2024 Revenue
Growth
Patent Status
Peak Sales
Elocta
SEK 4,891M
+1%
US: Expired; EU: ~2029
Declining
Alprolix
SEK 2,372M
+12%
US: 2026; EU: 2029
SEK 2.5-3B
Doptelet
~SEK 3,447M
+42%
~2030s
SEK 5-6B
Aspaveli
~SEK 1,000M
+44%
Apellis license
SEK 2-3B
Vonjo
SEK 706M
Strong
FDA 2022
SEK 2-3B
Immunology & Specialty Care Portfolio
Product
FY 2024 Revenue
Growth
Patent Status
Peak Sales
Kineret
SEK 2,854M
+18%
Off-patent
SEK 3-3.5B
Gamifant
~SEK 1,877M
+32%
Orphan exclusivity
SEK 3-4B
Synagis
SEK 2,422M
Declining
Mature
SEK 1-1.5B
Beyfortus Royalties
SEK 3,010M
+161%
Sanofi partnership
SEK 2-3B
5. Top 5 CEO Focus Drugs
1. Altuvoct - "Category-Leading Hemophilia A Treatment"
Once-weekly dosing; near-normal factor levels. Capturing switches from Elocta; competing with gene therapy narrative.
2. Gamifant - "Transforming HLH Treatment"
Revenue ~SEK 1,877M with +32% growth. Expanding into secondary HLH and MAS.
3. Doptelet - "Fastest-Growing Asset"
Q4 2024 alone SEK 1,147M (+56%). US market dominance with European expansion.
4. Aspaveli - "PNH Franchise Builder"
+44% Q4 YoY growth. Building complement franchise in Europe with nephrology expansion coming.
PITCH HOOK: "CAPS patients experience a median 7.3-year diagnostic delay, with some waiting over 70 years for diagnosis. The pattern of recurrent fever, rash, and joint pain triggered by cold or appearing without infectious cause creates a distinctive symptom signature that AI assessment can identify, potentially compressing years of diagnostic wandering into weeks."
FMF PITCH: "54% of FMF patients wait over 10 years for diagnosis, with 84% misdiagnosed—most commonly as appendicitis (55%) or acute rheumatic fever (45%). The pattern of recurrent self-limited fever with abdominal pain, particularly in individuals of Armenian, Turkish, or Middle Eastern descent, is a high-value target for AI-driven rare disease identification."
Aspaveli for PNH (Score: 8/10)
PITCH HOOK: "40% of PNH patients experience life-threatening blood clots BEFORE receiving a diagnosis, and fewer than 40% are diagnosed within 12 months of symptom onset. The triad of unexplained severe fatigue, dark or cola-colored urine, and recurrent abdominal pain represents a high-value diagnostic pattern where AI-driven symptom assessment can accelerate recognition of this treatable but deadly rare disease."
References
Sobi Q4 and FY 2024 Report Presentation. February 2025. Link